Toxicity and Outcomes of Ibrutinib in Chronic Lymphatic Leukemia-Real-World Results from the Study of 215 Patients in Argentina

Horacio Fernández Grecco¹, Pablo Valdemoros¹, Maria Jose Mela Osorio², Miguel Pavlovsky², Carolina Pavlovsky², Astrid Pavlovsky², Juan Dupont³, Dardo Riveros³, Juan Altuve³, Gonzalo Ferini⁴, Victoria Otero⁴, Fernando Warley⁴, Fernando Bezares⁵, Alicia Enrico⁶, Laura Kornblihtt⁷, Silvana Cugliari⁸, Augusto Mirolí⁹, Manuel Bonder¹⁰, Alicia Bistman¹¹, Julio Pose¹², Marta Zerga¹³, María Cabrejo¹, Jorge Jerez¹, Maria Cardenas¹⁴, Patricio Pereyra¹⁵, Juan Maradei¹⁶, Ana Portalez¹⁷, Fernanda Tosin¹⁸, Virginia Gilli¹⁹, Rodrigo Vallejo²⁰, Noelia Masachessi²¹, Eriberto Roveri²², Susana Mari²³, Magali Colucci²⁴, Basilio Pertiné²⁵, Noemi Pintos²

¹Department of Hematology, Sanatorio Julio Mendez, Buenos Aires, Argentina
²Department of Hematology, Fundaleu, Buenos Aires, Argentina
³Department of Hematology, Centro de Educacion Medica e Investigacion Clinica, Buenos Aires, Argentina
⁴Department of Hematology, Hospital Italiano, Buenos Aires, Argentina
⁵Department of Hematology, Hospital Alvarez, Buenos Aires, Argentina
⁶Department of Hematology, Hospital Italiano La Plata, Buenos Aires, Argentina
⁷Department of Hematology, Hospital de Clinicas Jose de San Martin Universidad de Buenos Aires, Buenos Aires, Argentina
⁸Department of Hematology, Instituto Roafi Universidad de Buenos Aires, Argentina
⁹Department of Hematology, Hospital Churruca, Buenos Aires, Argentina
¹⁰Department of Hematology, Sanatorio Trinidad Mitre, Buenos Aires, Argentina
¹¹Department of Hematology, Hospital Ramos Mejia, Buenos Aires, Argentina
¹²Department of Hematology, Sanatorio Otamendi, Buenos Aires, Argentina
¹³Department of Hematology, Hospital Aleman, Buenos Aires, Argentina
¹⁴Department of Hematology, Hospital Italiano San Justo, Buenos Aires, Argentina
¹⁵Department of Hematology, Hospital Posadas, Buenos Aires, Argentina
¹⁶Department of Hematology, Hospital Emilio Ferreyra, Bahia Blanca, Argentina
¹⁷Department of Hematology, Hospital Centeno, La Pampa, Argentina
¹⁸Department of Hematology, Hospital El Cauce, Buenos Aires, Argentina
¹⁹Department of Hematology, Hospital Entre Rios, Entre Rios, Argentina
²⁰Department of Hematology, Hospital Bernardo Houssay, Buenos Aires, Argentina
²¹Department of Hematology, Centro Oncologico San Luis, San Luis, Argentina
²²Department of Hematology, Sanatorio Norte Rosario, Santa Fe, Argentina
²³Department of Hematology, Hospital Blas Dubary, Buenos Aires, Argentina
²⁴Department of Hematology, Instituto Conciencia, Neuquen, Argentina
²⁵Department of Hematology, Instituto Medico de Alta Complejidad, Salta, Argentina

Email address:
horaciogreccof@hotmail.com (Horacio Fernández Grecco), pablo.valdemoros@gmail.com (Pablo Valdemoros), mjmelao@fundaleu.org.ar (Maria Jose Mela Osorio), mpavlovsky@fundaleu.org.ar (Miguel Pavlovsky), cpavlovsky@fundaleu.org.ar (Carolina Pavlovsky), astridp@intramed.net (Astrid Pavlovsky), jdupont643@gmail.com (Juan Dupont), dardoriveros@hotmail.com (Dardo Riveros), jialtuve@hotmail.com (Juan Altuve), gonzalo.ferini@hospitalitaliano.org.ar (Gonzalo Ferini), victoria.oterod@hospitalitaliano.org.ar (Victoria Otero), fernando.warley@hospitalitaliano.org.ar (Fernando Warley), raybezares@gmail.com (Fernando Bezares), aliciaenricomattos@gmail.com (Alicia Enrico), lauko09@gmail.com (Laura Kornblihtt)
Abstract: Different pivotal works allowed the approval of ibrutinib as a CLL treatment, both in the first line and in relapsed/refractory patients, the adverse effects differ from conventional chemotherapy, the discontinuation rate was 10%, but in different real-life studies, showed a higher number of complications and medication suspension rates of 40 to 50%. To know the reality of the use of ibrutinib in CLL in our environment, we designed this work with the objectives of evaluating the safety profile of the drug with the description of the adverse effects, their incidence, and their severity. The clinical efficacy will also be studied with the determination of the response achieved, calculation of overall survival (OS) and progression-free survival. Also as an additional objective, the discontinuation rate and its causes will be obtained. A total of 215 patients in 26 centers throughout the country were retrospectively analyzed. 189 patients (88%) had a global response, and the majority 58% achieved a partial response. The 5-year overall survival was 60%, with no difference between patients with different numbers of previous lines. The progression-free survival of the entire group was 5.06 years. 44.7% of the population presented at least 1 adverse effect. The most frequent ones were: bleeding, thrombocytopenia, pneumonia and diarrhea. Others presented: anemia, neutropenia, infections, AF, HTA, arthralgia, rash, opportunistic infections. Most adverse events were mild to moderate in grade and generally occurred within the first 6 months. The main cause of treatment suspension was the appearance of adverse effects, 37 patients had to suspend it, 27 due to adverse effects (72.97%). In our work, we found that ibrutinib, as a single agent, has outstanding activity in CLL, with a significant percentage of overall responses, even in patients with several lines of prior treatment. Most of the adverse effects were of a mild to moderate degree. The cardiovascular effects of TKI, HBP, and AF, are in percentages similar to those reported in other studies. If we analyze the percentage of treatment discontinuation, which is 17%, mostly due to adverse effects, this finding is similar to pivotal studies. In conclusion, our real-life study confirms the important activity of ibrutinib in patients with CLL, in the first line and relapses, highlighting the low percentage of treatment discontinuation in our environment. We believe our work reflects the real life and daily care of patients with CLL, under treatment with ibrutinib in our environment.

Keywords: Ibrutinib, Toxicities, Real Word

1. Introduction

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, with a mean age at diagnosis of 71 years. This disease is characterized by a clonal expansion of morphologically mature and immunologically incompetent B lymphocytes, CD5+ and CD23+. They accumulate in the blood, bone marrow, spleen, and lymph nodes. [1, 2-7].

The patients who required treatment received different chemoimmunotherapy schemes, which are difficult to carry out in elderly patients and patients with poor prognostic factors, such as 17p or alterations in the TP53 gene, present worse clinical evolution and shorter survival. [1]. In recent years, new drugs have emerged with advances in understanding the disease's biology.

The discovery of the role of Bruton tyrosine kinase (BTK) in the survival of B lymphocytes allowed the emergence and development of BTK inhibitor drugs such as ibrutinib. [7].

Ibrutinib binds covalently to BTK through cysteine at position 481, it is an irreversible inhibitor, with a potent inhibitory effect for more than 24 hours and a half-life of 2 to 3 hours.

In vivo and in vitro studies have shown that ibrutinib
inhibits the survival, proliferation, and migration of CLL cells.

It is the first BTK inhibitor to be approved for the treatment of CLL and other lymphoproliferative diseases such as mantle lymphoma. [3-4].

This approval was the result of various clinical studies: the RESONATE study showed that ibrutinib significantly prolonged progression-free survival and overall survival at 12 months (90 vs 81%), compared with ofatumumab in relapsed/refractory patients with LLC.

It maintained its positive results even in high-risk or unfavorable subgroups such as patients with 17p.

In RESONATE II, ibrutinib was compared with chlorambucil in patients with CLL, without previous treatment, showing favorable results in terms of progression-free survival was 90% at 18 months in the ibrutinib group and 52% in the group of chlorambucil. [3].

When overall survival was compared, it was 98% with ibrutinib versus 85% in the chlorambucil group.

The aforementioned studies, and others, showed the important activity of ibrutinib in this pathology and led to the approval of this drug for use both in the first line and in relapsed/refractory patients.

Although it does not present the typical adverse effects of chemotherapy, it has a characteristic profile of adverse effects, among which the most frequent are: diarrhea, gastrointestinal disturbances, infections, especially of the upper respiratory tract, pneumonia, opportunistic infections, rash, arthralgia, and less frequent but significant from the clinical point of view, hypertension, AF and bleeding. [5-12, 14].

On the other hand, it requires continuous administration until progression or intolerance, so data on adverse effects and safety are important.

It is common to find a discrepancy in the results of clinical studies compared to studies carried out in the so-called real world or real life, especially in the area of oncology. In the case of ibrutinib, in general, these latter studies showed a greater number of adverse effects and a higher rate of abandonment or discontinuation of the medication. [1-3].

For example, real-life jobs reported a higher incidence of opportunistic infections, and a discontinuation rate close to 40-50%. [13, 15-16]

Clinical studies generally enroll younger patients, with fewer comorbidities and with better general conditions than in usual clinical practice.

For this reason, knowledge of the real world is increasingly important, especially with new molecules and especially those that require continuous use until progression.

To know the reality in our environment regarding the use of ibrutinib, we designed this study.

2. Goals

Primary: Evaluate the safety profile of the drug with the description of the adverse effects, their incidence, and their severity.

The clinical efficacy will also be studied with the determination of the response achieved, the calculation of overall survival (OS) and progression-free survival.

Also as an additional objective, the discontinuation rate and its causes will be obtained.

3. Materials and Methods

Retrospective, descriptive, multicenter study of patients with CLL who received ibrutinib as monotherapy, in the first line or in subsequent lines between March 1st, 2016, and March 1st, 2021. The treating physicians had to complete the requested information in an Excel spreadsheet.

The severity of the adverse effects was reported according to the CTCAE in its version 5.0 of November 2017.

The response degrees were established according to the iw LLC guidelines.

CLL patients older than 18 years were included.

Patients who received ibrutinib in combination with another CLL medication, for example, anti-CD20 antibodies, were excluded.

Overall survival was defined as the time from the start of ibrutinib treatment until death from any cause. Data from patients who were alive were censored on the last contact date.

Survival function estimates were made using the Kaplan-Meier method, and the comparison between strata of said functions was based on the log-rank test. Hazard ratios were estimated using stratified Cox proportional hazards models. In a complementary way, the restricted mean survival times were calculated.

In the description of quantitative variables, mean and standard deviation were used for cases of normal distributions, or median and interquartile range for the others.

All tests were performed at 5% significance, and interval estimates at 95% confidence.

All analyzes were performed using Stata software, version 16.0.

4. Results

A total of 215 patients were evaluated, 108 were treated in 14 centers in the Autonomous City of Buenos Aires (CABA), 33 patients were treated in 5 centers in the Province of Buenos Aires (PBA) and the rest were reported by 7 centers in the interior of the country.

The clinical and demographic characteristics of the patients are shown in table 1.

<table>
<thead>
<tr>
<th>Table 1. Clinical and demographic characteristics of the patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
</tr>
<tr>
<td>Sex n%</td>
</tr>
<tr>
<td>A: 39</td>
</tr>
<tr>
<td>Staging Binet, n</td>
</tr>
<tr>
<td>Staging Rai, n</td>
</tr>
</tbody>
</table>
ECOG%  
0: 60%  
I: 26%  
II: 10%  
III a V: 4%  
0: 19

CIRS n.*  
I- II: 35  
III-IV: 28  
mas de V: 42

Previous line of treatment n.*  
Without treatment: 83 (38,6%)  
1 ó 2 previous lines: 108 (50.23%)  
3 previous lines: 18 (8,37%)  
4 o more lines: 6 (2,79%)  
Normal: 89 (60,96%)  
Not done: 41 (28,08%)  
Complex karyotype: 12 (8,22%)  
Others alterations: 4 (2,74%)  
del 17 (p) absent: 152 (73,08%)  
del 17 (p) present: 56 (26,92%)

The median follow-up was 67.6 months.  
The IGVH mutational status was performed only in 118 patients, 54.9% of the total population. Of these 118 patients, 66 patients, 30.84%, were non-mutated, and 51 patients were mutat ed, 43.22%.

The rest of the studies that are usually carried out by FISH, such as 13q, 11q, trisomy 12 or alterations in p53, were carried out in a minority of patients, so they could not be analyzed for the study.

Response to treatment with ibrutinib:  
The mean continuous exposure to the medication was 14.7 months.

189 patients (88%) had a global response, the majority 58% achieved a partial response and only 30% of the total study population achieved a complete response. The rest of the patients had stable disease or progressed. Figure 1.
The table shows the frequency of the different side effects:

**Table 2. Frequency of adverse effects.**

<table>
<thead>
<tr>
<th>HEMATOLOGICAL (n°, patients, %)</th>
<th>NON HEMATOLOGIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleeding: 20 (9.3%)</td>
<td>Pneumonia: 24 (11.2%)</td>
</tr>
<tr>
<td>Thrombocytopenia: 19 (8.8%)</td>
<td>Diarrhea: 22 (10.2%)</td>
</tr>
<tr>
<td>Anemia: 16 (7.4%)</td>
<td>Infection: 21 (9.8%)</td>
</tr>
<tr>
<td>Neutropenia: 12 (5.6%)</td>
<td>AF: 21 (9.8%)</td>
</tr>
</tbody>
</table>

Other adverse effects reported were: hypertension (7.4%); arthralgia (6%); rash (5.1%) and opportunistic infections (3.3%).

Of the 7 patients with opportunistic infections, 4 of them had had 1 or more lines of medical treatment.

The severity of adverse events was defined according to CTCAE version 5.0 of November 2017. Mild to moderate adverse events were considered to be those of grades 1-2, of said classification.

Most adverse events were mild to moderate in grade and generally occurred within the first 6 months, but some cases may occur up to 2 years and longer. Table 3. Figure 6.

**Table 3. Severity of adverse events.**

<table>
<thead>
<tr>
<th>Adverse effects</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>4</td>
<td>19</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>13</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Infection</td>
<td>10</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>AF</td>
<td>7</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Bleeding</td>
<td>12</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>8</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Anemia</td>
<td>7</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>High blood pressure</td>
<td>9</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>8</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>2</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Rash</td>
<td>6</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Opportunistic infection</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

The main reason for discontinuing treatment was the appearance of adverse effects, 37 patients had to discontinue, 27 due to adverse effects (72.97%) and 10 patients due to progression, 5 of them with Richter syndrome.

As expected, the suspension affected the evolution, and the global survival was significantly lower, 3.14 years, in the group that suspended the treatment. Figure 7.

If we analyze because of discontinuation, survival in patients who discontinued due to progression is much lower. 4.92 years vs. 2.79. Figure 8.

19 patients reduced the dose, with no change in survival. Figure 9.

During the study period, 13 patients died, 13.08% of the included patients.

**5. Discussion**

In our work, we found that ibrutinib, as a single agent, has outstanding activity in CLL, with a significant percentage of
overall responses, even in patients with several lines of prior treatment.

The overall response of 88% is similar to the pivotal studies.

The global survival rate in our work is 5.06 years, observing that patients with deletion 17p had less chance of survival but didn’t reach a statistically significant difference, showing the important activity of ibrutinib in these type of patients.

Initial studies with Ibrutinib suggested that the progression of the disease was the main cause of discontinuation of treatment. On the contrary our work demonstrated that the appearance of adverse effects or intolerance was the main cause of suspension of treatment with Ibrutinib. In our work the percentage of treatment discontinuation, which is 17%, this finding is similar to pivotal studies (where it is 10%), but it is different from other real-life studies, in different countries, where the suspension rate reaches between 40 and 50%. [1-2]

This difference could be because most of the events are mild to moderate and could be managed with symptomatic medication and, on the other hand, to the fact that access to other therapeutic alternatives is difficult for the different health subsystems in our country.

It should be noted that close to 45% of the patients presented at least 1 adverse effect.

Analyzed in general, most of the adverse effects appear within the first 6 to 12 months of treatment, and some of them, such as pneumonia and infections, can appear up to 2 years after treatment but tend to decrease over time.

In our work, we divided adverse events into hematological and non-hematological.

Among the hematological, the most frequent were bleeding (9.3%) and thrombocytopenia (8.8%), the non-hematological, the 2 most found were pneumonia (11.2%) and diarrhea (10.2%).

Most of the adverse effects were of a mild to a moderate degree and only 8 patients had severe events.

Regarding the cardiovascular effects of TKI, HBP and AF, they were not the most frequent among non-hematological events and are in percentages similar to those reported in other studies.

Another interesting fact to highlight, which requires future prospective studies, is that the patients who reduced the dose of ibrutinib did not see their overall survival affected.

Regarding opportunistic infections, they occurred in a low percentage of patients, and more than half of the cases had at least 1 line of prior treatment.

6. Conclusion

Our real-life study confirms the important activity of ibrutinib in patients with CLL, in the first line and relapses, with a tolerable safety profile, highlighting the low percentage of treatment discontinuation in our environment.

Although our study has some limitations, such as its retrospective nature, we believe it reflects the real life and daily care of patients with CLL, under treatment with ibrutinib in our environment, given the participation of numerous health centers from different parts of our country.

References


